Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

György Nagy

Showing results (1-10 of 137) with videos related to

Pageof 14
Sort By:
Orvosi Hetilap|April 26, 2026
[The effect of physiotherapy treatments on the immune system]Tamás Bender, György Nagy
Rheumatology (Oxford, England)|October 23, 2023
Viewpoint: Could better understanding of risk factors for comorbidities pave the way towards personalized therapy in rheumatoid arthritis?Judit Majnik, György Nagy
Reumatologia|December 5, 2025
Obstetric antiphospholipid syndrome: evolving classification and implications for clinical practice and researchJudit Végh, György Nagy
Orvosi Hetilap|October 2, 2022
Influenza as a threat to cardiovascular health and the role of vaccination in risk reductionZsolt Körömi, Gergely György Nagy
RMD Open|November 12, 2025
Strengths and limitations of the EULAR definition for difficult-to-treat rheumatoid arthritisGyörgy Nagy, Maya H Buch
The Lancet. Rheumatology|April 18, 2026
Lifestyle factors in difficult-to-treat rheumatoid arthritisLilla Gunkl-Tóth, György Nagy
Arthritis Research & Therapy|August 4, 2015
Sustained biologic-free and drug-free remission in rheumatoid arthritis, where are we now?György Nagy, Ronald F van Vollenhoven
Arthritis Research & Therapy|August 15, 2009
Rheumatoid arthritis and smoking: putting the pieces togetherZsuzsanna Baka, Edit Buzás, György Nagy
Annals of the Rheumatic Diseases|June 17, 2022
Synovial fibroblasts as potential drug targets in rheumatoid arthritis, where do we stand and where shall we go?Tamás Németh, György Nagy, Thomas Pap
Rheumatology (Oxford, England)|October 7, 2022
Comorbidities and extra-articular manifestations in difficult-to-treat rheumatoid arthritis: different sides of the same coin?Mrinalini Dey, György Nagy, Elena Nikiphorou
Pageof 14

Showing results (1-10 of 137) with videos related to

Sort By:
Pageof 14
Orvosi Hetilap|April 26, 2026
[The effect of physiotherapy treatments on the immune system]Tamás Bender, György Nagy
Rheumatology (Oxford, England)|October 23, 2023
Viewpoint: Could better understanding of risk factors for comorbidities pave the way towards personalized therapy in rheumatoid arthritis?Judit Majnik, György Nagy
Reumatologia|December 5, 2025
Obstetric antiphospholipid syndrome: evolving classification and implications for clinical practice and researchJudit Végh, György Nagy
Orvosi Hetilap|October 2, 2022
Influenza as a threat to cardiovascular health and the role of vaccination in risk reductionZsolt Körömi, Gergely György Nagy
RMD Open|November 12, 2025
Strengths and limitations of the EULAR definition for difficult-to-treat rheumatoid arthritisGyörgy Nagy, Maya H Buch
The Lancet. Rheumatology|April 18, 2026
Lifestyle factors in difficult-to-treat rheumatoid arthritisLilla Gunkl-Tóth, György Nagy
Arthritis Research & Therapy|August 4, 2015
Sustained biologic-free and drug-free remission in rheumatoid arthritis, where are we now?György Nagy, Ronald F van Vollenhoven
Arthritis Research & Therapy|August 15, 2009
Rheumatoid arthritis and smoking: putting the pieces togetherZsuzsanna Baka, Edit Buzás, György Nagy
Annals of the Rheumatic Diseases|June 17, 2022
Synovial fibroblasts as potential drug targets in rheumatoid arthritis, where do we stand and where shall we go?Tamás Németh, György Nagy, Thomas Pap
Rheumatology (Oxford, England)|October 7, 2022
Comorbidities and extra-articular manifestations in difficult-to-treat rheumatoid arthritis: different sides of the same coin?Mrinalini Dey, György Nagy, Elena Nikiphorou
Pageof 14